查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球分子乳房影像市場 - 2023-2030
市場調查報告書
商品編碼
1374854

全球分子乳房影像市場 - 2023-2030

Global Molecular Breast Imaging Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

分子乳房影像也稱為閃爍X光攝影、核醫乳房影像和乳房特異性伽馬成像，是一種先進的、經 FDA 批准的成像技術，用於識別乳房組織緻密的女性的乳癌。分子乳房影像使用特殊的相機和少量放射性追蹤劑來突出組織活動的差異，並將健康、緻密的組織與乳房不規則的組織區分開來。這是一項高度準確的影像研究，丟失癌細胞的可能性很低。

此外，透過靜脈注射管向患者施用少量放射性示蹤劑。該示踪劑被快速分裂的細胞（包括癌細胞）迅速吸收，並在成像結果上突出顯示。患者將乳房放在一個類似乳房X光檢查機的特殊平台上。輕輕擠壓乳房，用特殊的伽瑪相機捕捉高品質影像，但這種輕微的擠壓不應引起不適。伽瑪相機記錄乳房組織活動約 20 分鐘。

市場動態：促進因素

越來越多採用分子乳房影像進行乳癌篩檢

分子乳房影像擴大用於乳癌篩檢，預計將在預測期內推動市場發展。分子乳房影像因其檢測乳癌的靈敏度較高而聞名，特別是對於乳房組織緻密的女性。它可以幫助識別單獨透過乳房X光檢查可能漏掉的腫瘤。準確性的提高是其採用的重要推動力。

此外，分子乳房影像通常與乳房X光攝影術一起用作補充篩檢工具。此外，在乳房 X 光檢查得出不確定結果或需要其他資訊時，這種影像技術可以透過降低錯過或延遲癌症診斷的風險來提供有價值的見解。

這種成像技術的不斷進步使其更易於使用。這些技術改進，例如數位伽瑪相機的開發和更舒適的成像程序，使其成為更具吸引力的選擇。通常建議高風險患者使用，例如有乳癌家族史或已知基因突變（如 BRCA1 和 BRCA2）的患者。早期檢測癌症的能力可以挽救這些人的生命。

例如，2021 年 2 月 9 日，SmartBreast Corporation 宣布與 FoxSemicon Integrated Technologies, Inc. (FITI) 建立合作夥伴關係，生產分子乳房成像 (MBI) 系統。 FITI 對 SmartBreast 進行了大量投資，並將成為 SmartBreast 最近收購的兩個 MBI 系統（GE Healthcare Discovery NM 750b 和 Dilon Technologies D6800）的合約製造商。 SmartBreast 將把這兩個系統分別重新命名為 EVE CLEAR SCAN e750 和 e680。 SmartBreast 和 FITI 將共同開發和製造創新、經濟高效的下一代 MBI 系統，以進一步提高早期癌症檢測的功效並提高採用率。

此外，乳癌盛行率的增加、FDA 對新型和先進乳房分子影像技術的批准不斷增加、增加臨床試驗以開發更先進的設備、提高人們對分子乳房影像設備開發的認知和進步，這些因素預計將推動乳房影像技術的發展。預測期內的市場。

限制

與分子乳房成像相關的併發症、與該成像技術相關的高成本、該測試無法檢測所有癌症以及分子乳房成像中的示踪劑可能產生過敏反應等因素預計將阻礙該市場。

目錄

第 1 章：方法與範圍

  • 研究方法論
  • 報告的研究目的和範圍

第 2 章：定義與概述

第 3 章：執行摘要

  • 按設計類型分類
  • 按模態分類
  • 按應用程式片段
  • 最終使用者的片段
  • 按地區分類

第 4 章：動力學

  • 影響因素
    • 促進要素
      • 提高乳癌篩檢的採用率
    • 限制
      • 分子乳房影像相關的併發症
    • 機會
    • 影響分析

第 5 章：產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • 未滿足的需求
  • DMI 意見

第 6 章：COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆發前的情景
    • 新冠疫情期間的情景
    • 新冠疫情後的情景
  • COVID-19 期間的定價動態
  • 供需譜
  • 疫情期間政府與市場相關的舉措
  • 製造商策略舉措
  • 結論

第 7 章：依設計類型

  • 放射性示踪劑
  • 伽瑪相機

第 8 章：按形態

  • 單頭伽瑪相機
  • 雙頭相機

第 9 章：按應用

  • 乳房檢查
  • 乳房診斷

第 10 章：最終用戶

  • 醫院
  • 診斷中心
  • 專科診所
  • 學術及研究機構
  • 其他

第 11 章：按地區

  • 北美洲
    • 11.2.3。按應用的市場規模分析和年成長分析 (%)
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 亞太其他地區
  • 中東和非洲

第 12 章：競爭格局

  • 競爭場景
  • 市場定位/佔有率分析
  • 併購分析

第 13 章：公司簡介

  • CMR Naviscan Corporation
    • 公司簡介
    • 產品組合和描述
    • 財務概覽
    • 主要進展
  • SmartBreast Corporation
  • DIGIRAD HEALTH, INC.

第 14 章：附錄

簡介目錄
Product Code: MI7378

Overview

Molecular breast imaging also known as scintimammography, nuclear medicine breast imaging and breast-specific gamma imaging, is an advanced and FDA-approved imaging technology that is used to identify breast cancer in women with dense breast tissue. Molecular breast imaging uses a special camera and a small amount of radioactive tracer to spotlight differences in tissue activity and differentiate healthy, dense tissue from breast irregularities. It is a highly accurate imaging study with a low chance of missing cancerous cells.

Moreover, a small amount of radioactive tracer is administered to the patient through an intravenous line. The tracer is swiftly absorbed by rapidly dividing cells, including cancer cells, and appears highlighted on imaging results. The patient places her breast on a special platform which is similar to that of a mammogram machine. The breast is gently compressed to capture high-quality images with a special gamma camera, but this light compression should not cause discomfort. The gamma cameras record the breast's tissue activity for about 20 minutes.

Market Dynamics: Drivers

Increasing adoption of molecular breast imaging for breast cancer screening

The increasing adoption of molecular breast imaging for breast cancer screening is expected to drive the market over the forecast period. Molecular breast imaging is known for its higher sensitivity in detecting breast cancer, particularly in women with dense breast tissue. It can help identify tumors that might be missed by mammography alone. This increased accuracy is a significant driver of its adoption.

Moreover, molecular breast imaging is often used as a complementary screening tool alongside mammography. Also, in cases where the mammograms yield inconclusive results or when additional information is needed, this imaging technique can provide valuable insights by reducing the risk of missed or delayed cancer diagnoses.

Ongoing advancements in this imaging technology have made it more accessible and easier to use. These technological improvements like the development of digital gamma cameras and more comfortable imaging procedures, make it a more attractive option. It is often recommended for high-risk patients such as those with a family history of breast cancer or known genetic mutations like BRCA1 and BRCA2. The ability to detect cancer at an earlier stage can be lifesaving for these individuals.

For instance, on February 9, 2021, SmartBreast Corporation released that it has formed a partnership with FoxSemicon Integrated Technologies, Inc. (FITI) to manufacture Molecular Breast Imaging (MBI) systems. FITI has invested substantially in SmartBreast and will be the contract manufacturer for two MBI systems recently acquired by SmartBreast, the GE Healthcare Discovery NM 750b and the Dilon Technologies D6800. SmartBreast will rebrand the two systems as EVE CLEAR SCAN e750 and e680, respectively. Together, SmartBreast and FITI will co-develop and manufacture innovative, cost-effective, next-generation MBI systems to further increase the efficacy of detecting cancer in the earlier stage and to increase the adoption.

Further, the increasing prevalence of breast cancers, rising FDA approvals for novel and advanced molecular imaging techniques for breast, increasing clinical trials to develop more advanced devices, increasing awareness and advancements in the development of molecular breast imaging devices are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications associated with molecular breast imaging, the high cost of associated with this imaging technique, this test can't detect all cancers and the tracer in the molecular breast imaging can develop allergic reactions are expected to hamper the market.

Segment Analysis

The global molecular breast imaging market is segmented based on design type, modality, application, end-user and region.

The gamma camera segment accounted for approximately 45.3% of the molecular breast imaging market share

The gamma camera segment is expected to hold the largest market share over the forecast period. The gamma camera in molecular breast imaging is mainly responsible for capturing images of the breast tissue after the injection of a radioactive tracer. It detects gamma rays emitted from the tracer, which is preferentially taken up by areas with increased metabolic activity, such as breast cancerous tumors.

Furthermore, the sensitivity of the gamma camera is crucial in detecting even small or low-activity tumors in the breast. This molecular breast imaging which consists of the gamma camera offers another option for women to be proactive about their breast health. Modern gamma cameras are designed for efficiency by allowing for quicker image acquisition and reduced radiation exposure for patients. Efficiency is a vital consideration, as it impacts patient comfort.

Additionally, the gamma cameras of molecular breast imaging often come equipped with advanced image processing and analysis software. These tools aid radiologists in interpreting the images, making the camera an integral part of the diagnostic process. The design and functionality of the gamma camera can significantly influence the patient's experience. A comfortable and well-designed camera can help reduce anxiety and improve the overall patient experience during the molecular breast imaging procedure.

Geographical Analysis

North America accounted for approximately 40.3% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing research activities. North America especially the United States is a hub for its strong presence of major players such as diagnostic companies and medical device companies. The presence of major players actively focusing on the development of more advanced molecular breast imaging by the technological advancements for better adoption along with better patient outcomes.

Furthermore, the increasing prevalence of breast cancer in the region is very high, which is considered to drive the market in the region. Due to the high prevalence of breast cancer in the region, it is known for the increased adoption for the diagnosis and screening of breast cancer. Early detection reduces the death rate of the patients by early detection and diagnosis.

For instance, according to the National Institute of Health (NIH), 2021, in the United States, there are over 250,000 new cases of breast cancer annually with over 46,000 women dying of the disease. Over the past two decades, the death rate from breast cancer has decreased by over 40%, a monumental achievement, due to the combination of improved detection as well as improved, increasingly targeted therapies. When breast cancer is detected early, over 95% of women survive more than five years.

Competitive Landscape

The major global players in the molecular breast imaging market include: CMR Naviscan Corporation, SmartBreast Corporation and DIGIRAD HEALTH, INC. among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global molecular breast imaging market. During the pandemic, molecular breast imaging procedures are postponed or canceled temporarily due to the redirected focus on the pandemic and its associated risks. Molecular breast imaging experienced a drop in patient volumes as people postponed routine visits. The pandemic disrupted supply chains for the components and materials needed for molecular breast imaging systems. Delays in the manufacturing and distribution of these components affected the availability of these imaging equipment.

Market Segmentation

By Design Type

  • Radioactive Tracer
  • Special Camera

By Modality

  • Single Head Gamma Camera
  • Dual Head Camera

By Application

  • Breast Screening
  • Breast Diagnosis

By End-User

  • Hospitals
  • Diagnostic Centers
  • Specialty Clinics
  • Academic and Research Institutes
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Why Purchase the Report?

  • To visualize the global molecular breast imaging market segmentation based on design type, modality, application, end-user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of molecular breast imaging market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global molecular breast imaging market report would provide approximately 48 tables, 59 figures, and 187 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Design Type
  • 3.2. Snippet by Modality
  • 3.3. Snippet by Application
  • 3.4. Snippet by End-User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Adoption for Breast Cancer Screening
    • 4.1.2. Restraints
      • 4.1.2.1. Complications Associated with Molecular Breast Imaging
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Unmet Needs
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Design Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design Type
    • 7.1.2. Market Attractiveness Index, By Design Type
  • 7.2. Radioactive Tracer*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Gamma Camera

8. By Modality

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 8.1.2. Market Attractiveness Index, By Modality
  • 8.2. Single Head Gamma Camera*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Dual Head Camera

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Breast Screening*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Breast Diagnosis

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Diagnostic Centers
  • 10.4. Specialty Clinics
  • 10.5. Academic and Research Institutes
  • 10.6. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 11.2.5. 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. CMR Naviscan Corporation*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. SmartBreast Corporation
  • 13.3. DIGIRAD HEALTH, INC.

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us